FDA Removes Warnings Against Unproven Autism Treatments Amid HHS Leadership Shift

The Policy Change

The Food and Drug Administration (FDA) recently removed a critical webpage that warned consumers about the dangers and ineffectiveness of various unproven autism treatments. This advisory, which had not been updated since 2019, explicitly cautioned against products and remedies such as chelating agents, hyperbaric oxygen therapies, chlorine dioxide, and raw camel milk, highlighting their deceptive marketing and potential for harm. The Department of Health and Human Services (HHS) stated the page was retired “during a routine clean up of dated content at the end of 2025,” a justification that has drawn significant criticism from autism advocacy groups and medical professionals.

This removal is viewed by many as aligning with the broader stance of HHS Secretary Robert F. Kennedy Jr., who has publicly expressed skepticism towards conventional science, particularly concerning vaccine safety and autism. Under his leadership, the agency has seen notable shifts, including the appointment of a vaccine critic who previously promoted the puberty-blocking drug Lupron for autistic children. Furthermore, Kennedy has reconstituted an advisory panel on autism, replacing members with established expertise with individuals who champion unproven remedies like pressurized oxygen chambers, infusions to draw out heavy metals (chelation), suramin, and controversial language techniques. These changes signal a potential pivot in federal health policy away from strictly evidence-based approaches for autism care.

The FDA’s long-standing position, dating back to at least 2010, has been to urge consumers against ingesting chlorine dioxide, often marketed as a “Miracle Mineral Solution,” due to its transformation into a dangerous bleach that can cause serious, life-threatening side effects. Despite these clear warnings, the chemical has been promoted by figures like Senator Ron Johnson, who endorsed a book describing it as a “remarkable molecule” capable of treating various conditions, including autism. The absence of official government warnings on such substances has been celebrated in certain online communities, further complicating public health messaging.

Impact on ABA

The removal of official government warnings against unproven autism treatments poses significant challenges for the Applied Behavior Analysis (ABA) field and the families it serves. When federal agencies like the FDA retract clear guidance on what constitutes safe and effective care, it can create a vacuum of information, making it harder for parents to distinguish between evidence-based therapies and potentially harmful alternatives. This ambiguity risks diverting families, who are often desperate for solutions, away from scientifically validated interventions like ABA, which has decades of research supporting its efficacy in improving adaptive behaviors and functional skills for individuals with autism spectrum disorder.

For BCBAs, RBTs, and ABA clinic owners, this policy shift could complicate client education and advocacy efforts. They may face increased pressure from families exploring unproven remedies, requiring them to spend more time counteracting misinformation and reinforcing the importance of evidence-based practice. The potential for harm from treatments like chelation therapy, which has been linked to fatalities, or hyperbaric oxygen therapy, which has resulted in deaths, underscores the critical role of clear, authoritative public health warnings. Without these, the credibility of established medical and therapeutic guidelines, including those supporting ABA, could be inadvertently undermined, potentially leading to poorer outcomes for individuals with autism.

Moreover, the reorientation of federal advisory panels to include proponents of unproven therapies could influence future research funding, policy recommendations, and even insurance coverage decisions. If federal policy begins to lend legitimacy to non-evidence-based approaches, it could create an uneven playing field, challenging the standards of care that ABA professionals strive to uphold. This environment necessitates heightened vigilance and advocacy from the ABA community to ensure that federal policy continues to prioritize interventions supported by rigorous scientific evidence.

Next Steps

The immediate aftermath of the FDA’s action and the changes within HHS suggests a period of continued debate and uncertainty regarding federal health policy for autism. Advocacy organizations like the Autistic Self Advocacy Network (ASAN) have voiced strong opposition, calling the reconfigured HHS autism panel “overwhelmingly made up of anti-vaccine advocates and peddlers of dangerous quack autism ‘treatments.'” This public discourse highlights a growing rift between evidence-based medical consensus and a segment of the public and political leadership. Experts like Dr. Paul Offit of Children’s Hospital of Philadelphia and Dr. Fred Volkmar of Yale University emphasize the importance of early diagnosis and proven treatments, noting that 70% to 75% of children on the autism spectrum can achieve full or semi-independence with effective interventions. They lament the government’s reduced role in guiding parents toward what “does and doesn’t work.”

Looking ahead, the ABA community and allied professionals must remain proactive in educating the public, advocating for policies grounded in scientific evidence, and ensuring that access to proven therapies is not jeopardized. The push for official studies into unproven remedies, as desired by some proponents, would need to adhere to rigorous scientific standards to be considered credible. The ongoing changes at the federal level underscore the need for continuous engagement with policymakers, clear communication with families, and unwavering commitment to ethical, evidence-based practice to safeguard the well-being of individuals with autism.

Fast Facts

Expert Perspective

It’s a shame that the federal government is not being more helpful to parents in understanding what does and doesn’t work.

Source: undark.org